knowledge -WSS

knowledge

author：leisure time 2025-09-28 22:52:50 - browse：644

The back of three medicine containers, a bottle in between two boxes, all showing labels — coverage from STAT — Adobe

After a drug enters the market, it’s up to Food and Drug Administration regulators to ensure its continued safety and efficacy. A recent New York Times story suggests that, in the case of the popular asthma drug Singulair, the FDA fell short — both because the agency delayed action for years on reports from patient advocates and independent groups that the drug could cause suicidal thoughts, and because when it did add a warning label about its potential side effects in 2020, clinicians and patients still weren’t always aware of the risks.

Experts say that the Singulair incident highlights a flawed system, both in the U.S. and globally, for monitoring adverse reactions after a drug is on the market — one that will require extensive changes to address.

“The question is, how safe do you want to be?” said Ameet Sarpatwari, the assistant director of the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital. Ideally, he said, the FDA should be able to both stay on top of safety concerns and avoid unnecessarily restricting access to drugs. “Are we at the right balance? I think there are definitely situations for many drugs where you can say, no, we’re not really at the right balance, and the FDA should be taking a more aggressive stance in promoting patient safety.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Judge schedules Friday hearing on proposed protective order in Jan. 6 case

entertainment

WSS

Ohioans vote in high

HHS leader on health, climate change and biopharma emissions

Mega Millions jackpot estimated at record $1.58 billion for Tuesday's drawing

Cheesesteak restaurant owner explains his secret sauce, the viral Malibu Barbie Dream Drizzle

In venture capital firm's success, lessons for turning crisis into profit

Solve the antibiotic resistance crisis with preventive drugs

leisure time

knowledge

explore

Guidelines to prevent youth baseball injuries need more muscle

Judge rejects Trump's counterclaim against E. Jean Carroll

United colonoscopy coverage change 'may cost lives,' doctors say

The painfully weak evidence on taking collagen to treat arthritis

New air purifier tech could be key to improving indoor air quality

STAT Summit: Michael J. Fox on progress in Parkinson's research

As demand for Covid shots wanes, Moderna seeks its next success

How climate

Medicare proposal to cover medical devices draws a mixed reaction

STAT Summit: Michael J. Fox on progress in Parkinson's research

entertainment

First Opinion Podcast: Long Covid needs a new approach

Travel bans should be based on evidence, not politics or fear

In venture capital firm's success, lessons for turning crisis into profit

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

STAT Readout Newsletter: Today's biggest biotech updates

leisure time

entertainment

knowledge

leisure time